Multiple Myeloma
Conditions
Interventions
Case series:reduced dosage
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Signed informed consent; aged 18 to 75 years; the cell morphology, flow cytometry analysis and examination confirmed the diagnosis of multiple myeloma patients accepted standard treatment efficacy after the poor, diagnosed with relapsed and refractory multiple myeloma; myeloma lesions in the screening period M protein test (obtained by serum / urine protein electrophoresis) to the determination of the level required to meet at least one of the following indicators: detection of serum M protein is more than 10g/L (protein electrophoresis) or IgA more than 7.5g/L (turbidimetry immunoglobulin quantitative) urine M protein is more than 0.2g/24h; ECOG score of 2 or less; expected survival of more than 3 month; laboratory examination results should meet the following requirements: at least the index absolute neutrophil count (ANC) = 1 *10^9/L; at least platelet (PLT) = 50 * 10^9/L; aspartate aminotransferase (AST/SGOT) is less than 2.5 * ULN; alanine aminotransferase ( ALT/SGPT) is less than 2.5 * ULN; alkaline phosphatase (ALP) is less than 2.5 * ULN; total bilirubin (TBIL) is less than 1.5 * ULN; at least creatinine clearance rate (Ccr) is 30ml/min
Exclusion criteria
Exclusion criteria: Stem cell transplantation, manifested as graft-versus-host disease, when informed consent illness was actived or required immunosuppressive therapy; a history of allergic reactions or contraindications to any drug test composition; 4 weeks received any routine or research the anti myeloma drug treatment (manual note for the anti myeloma therapy; thalidomide maintenance treatment shortened to 2 weeks before the test (if) or radiotherapy had received radiotherapy can shorten the time limit to test before 2 weeks); 2 weeks underwent major surgery; plasma cell leukemia; combined with other malignant tumor with poorly controlled hypertension or; clinical significance (such as activity) of cardiovascular and cerebrovascular diseases, such as cerebrovascular accident (signed informed consent before 6 months), myocardial infarction (signed informed consent before 6 months) Unstable angina, New York Heart Association class II or above the level of congestive heart failure or severe arrhythmia or poor control of the potential impact on the study of treatment; combined with other serious organic disease and suffering from mental disorders; need treatment systemic active infection; known HIV positive patients or clinical the activity of the A, B and C hepatitis; pregnancy or breast-feeding women; dementia, mental abnormalities or any informed consent for understanding mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| immunofixation electrophoresis; | — |
Countries
China
Contacts
Public ContactFang Baijun
He'nan Cancer Hospital
Outcome results
None listed